Funding for this research was provided by:
National Taiwan University Hospital, Hsinchu Branch (106-HCH028, 107-HCH009)
Ministry of Science and Technology, Taiwan (107-2314-B-002-259-MY3)
Article History
First Online: 23 September 2019
Compliance with Ethical Standards
:
: This study was supported by the National Taiwan University Hospital, Hsinchu Branch (106-HCH028 and 107-HCH009) and the Ministry of Science and Technology, Taiwan (formerly, the National Science Council; Grant Numbers, MOST 107-2314-B-002-259-MY3).
: Dr. Tsen-Fang Tsai has conducted clinical trials or received honoraria for serving as a consultant for Abbvie, Boehringer Ingelheim, Celgene, Eli-Lilly, Galderma, GSK, Janssen-Cilag, Leo Pharma, Merck-Serono, Novartis International AG, and Pfizer Inc. Dr. Hsien-Yi Chiu have received speaking fees from AbbVie, Eli-Lilly, Novartis Pharmaceuticals Corporation, Janssen-Cilag Pharmaceutica, and Pfizer Limited. Other authors have no conflicts of interest to declare.
: The study protocol was reviewed and approved by the local Institutional Review Board of the National Taiwan University Hospital, Hsinchu branch (105-069-E) and informed consent had been obtained from each patient.